The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

被引：15

作者：

Garcia, Christine ^{[1
]}

Ring, Kari L. ^{[1
]}

机构：

[1] Univ Virginia, Thorton Div Gynecol Oncol, Dept Obstet & Gynecol, 1215 Lee St, Charlottesville, VA 22902 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2018年 / 19卷 / 12期

关键词：

Programmed death ligand-1; Immunotherapy; Gynecologic cancer; Ovarian cancer; Endometrial cancer; Cervical cancer; TUMOR-INFILTRATING LYMPHOCYTES; CELL LUNG-CANCER; HUMAN-PAPILLOMAVIRUS; IMPROVED SURVIVAL; T-CELLS; ANTI-PD-L1; ANTIBODY; ANTITUMOR-ACTIVITY; OVARIAN-CARCINOMA; NEOANTIGEN LOAD; LYNCH SYNDROME;

D O I：

10.1007/s11864-018-0593-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Opinion statementActivity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.

引用

页数：14

共 50 条

[1] The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
Christine Garcia
Kari L. Ring
Current Treatment Options in Oncology, 2018, 19
[2] PD-1/PD-L1 checkpoint in hematological malignancies
Annibali, O.
Crescenzi, A.
Tomarchio, V.
Pagano, A.
Bianchi, A.
Grifoni, A.
Avvisati, G.
LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
[3] PD-1 checkpoint inhibition: Toxicities and management
Hahn, Andrew W.
Gill, David M.
Agarwal, Neeraj
Maughan, Benjamin L.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (12) : 701 - 707
[4] Structural basis of PD-1/PD-L1 checkpoint inhibition
Magiera, K.
Zak, K.
Berlicki, L.
Domling, A.
Holak, T.
Dubin, G.
FEBS JOURNAL, 2017, 284 : 45 - 45
[5] Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Bewersdorf, Jan Philipp
Shallis, Rory M.
Zeidan, Amer M.
BLOOD REVIEWS, 2021, 45
[6] The role of immune checkpoint PD-1 in the submandibular gland
Borys, Samantha
Brossay, Laurent
JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
[7] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, Dongxu
Lin, Jianzhen
Yang, Xu
Long, Junyu
Bai, Yi
Yang, Xiaobo
Mao, Yilei
Sang, Xinting
Seery, Samuel
Zhao, Haitao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
[8] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Dongxu Wang
Jianzhen Lin
Xu Yang
Junyu Long
Yi Bai
Xiaobo Yang
Yilei Mao
Xinting Sang
Samuel Seery
Haitao Zhao
Journal of Hematology & Oncology, 12
[9] The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis
Xu, Wenhua
Cui, Jiajun
Wu, Linqing
He, Caigu
Chen, Gang
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 426
[10] Molecular and clinical analyses of patients with gynecologic malignancies treated with PD-1 directed immunotherapy
Chae, Young Kwang
Murshudova, Sabina
Bae, William H.
Anker, Jonathan F.
Pineda, Mario J.
Nieves-Neira, Wilberto
Matei, Daniela E.
Lurain, John R.
Shahabi, Shohreh
Giles, Francis J.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →